Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.

Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH.

Arch Gen Psychiatry. 2008 Aug;65(8):870-80. doi: 10.1001/archpsyc.65.8.870.

PMID:
18678792
2.

[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].

Gourion D.

Encephale. 2008 Jan;34(1):73-81. doi: 10.1016/j.encep.2007.12.001. Epub 2008 Feb 5. Review. French.

PMID:
18514154
3.

Bupropion: a review of its use in the management of major depressive disorder.

Dhillon S, Yang LP, Curran MP.

Drugs. 2008;68(5):653-89. Review. Erratum in: Drugs. 2008;68(7):980.

PMID:
18370448
4.

Dose-response relationship with venlafaxine.

Kelsey JE.

J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):21S-26S; discussion 26S-28S. Review.

PMID:
8784645
6.

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN.

Ann Intern Med. 2008 Nov 18;149(10):734-50. Review.

PMID:
19017592
7.

[Severe forms of depression: the efficacy of escitalopram].

Spadone C.

Encephale. 2009 Apr;35(2):152-9. doi: 10.1016/j.encep.2008.09.008. Epub 2009 Mar 31. Review. French.

PMID:
19393384
8.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
9.

Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose.

Sussman N.

Postgrad Med. 1999 Nov;106(6 Suppl):31-6. doi: 10.3810/pgm.11.1999.suppl1.5. Review.

PMID:
19667502
10.

Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.

Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA.

Expert Rev Neurother. 2007 Jun;7(6):603-15. Review.

PMID:
17563244
11.

Venlafaxine: a 2003 update.

Gutierrez MA, Stimmel GL, Aiso JY.

Clin Ther. 2003 Aug;25(8):2138-54. Review.

PMID:
14512125
12.

Bupropion extended-release for depressive disorders.

Jefferson JW.

Expert Rev Neurother. 2008 May;8(5):715-22. doi: 10.1586/14737175.8.5.715. Review.

PMID:
18457528
13.

[Escitalopram--second generation of serotonin transporter inhibitors?].

Rybakowski J, Borkowska AB.

Psychiatr Pol. 2004 Mar-Apr;38(2):227-39. Review. Polish.

PMID:
15307289
14.

[Effects of venlafaxine extended release formulation on the clinical management of patients].

Carrasco JL, Díaz-Marsá M, López-Ibor JJ.

Actas Esp Psiquiatr. 2005 May-Jun;33(3):147-53. Review. Spanish.

PMID:
15918081
15.

Bupropion sustained release: a therapeutic overview.

Davidson JR, Connor KM.

J Clin Psychiatry. 1998;59 Suppl 4:25-31. Review.

16.

Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.

Kamijima K, Aoki M.

Expert Rev Neurother. 2006 Jul;6(7):945-56. Review.

PMID:
16831110
17.

Improving antidepressant adherence.

Nemeroff CB.

J Clin Psychiatry. 2003;64 Suppl 18:25-30. Review.

18.

Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.

Kornstein SG.

Expert Rev Neurother. 2008 May;8(5):737-42. doi: 10.1586/14737175.8.5.737. Review.

PMID:
18457530
19.

Bupropion sustained release: side effect profile.

Settle EC Jr.

J Clin Psychiatry. 1998;59 Suppl 4:32-6. Review.

20.

Spotlight on bupropion in major depressive disorder.

Dhillon S, Yang LP, Curran MP.

CNS Drugs. 2008;22(7):613-7. Review.

PMID:
18547129

Supplemental Content

Support Center